The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

ESC Congress 2025 highlights – The latest trials and updated ESC guidelines: A UK perspective

29 September 2025
Dr Sarah Birkhoelzer and Dr Ahmed Alsobhi review the latest trial data revealed at this year's ESC congress and discuss the 2025 guideline updates. What does this all mean in real terms for UK clinicians?
  • What is the role of beta-blockers in contemporary practice?
  • Do wearables and active monitoring for atrial fibrillation really work?
  • Controlled potassium levels: is hyperkalaemia a treatment effect or a side effect?
  • New valvular heart disease guidelines for 2025
  • A focused updated on dyslipidaemia
Speakers

Dr Sarah Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospital Dorset
Dr Ahmed Alsobhi, Cardiology Research Fellow, University Hospital of Southampton 

 

Categories

Tags

ESC Congress 2024 highlights – A UK perspective: What’s new in the latest ESC guideline update?

  • Paul Foley, Terry McCormack

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

© 2025 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.